• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Psychiatry Classics

The STAR*D trials I: Medication augmentation for depression [Classics Series]

byAndrew Cheung, MD MBA
November 9, 2014
in Psychiatry Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients who have not experienced remission of depression despite vigorous treatment with an SSRI, augmentation of treatment by adding buproprion or buspirone can achieve remission in approximately 30% of patients.

2. There were no significant differences between the two groups in terms of remission rates.

Original Date of Publication: March 2006

The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trials explored the management of patients who had refractory depression despite treatment with a selective serotonin-reuptake inhibitor (SSRI). Two papers were published based on data from the STAR*D trials in NEJM in 2006, which involved outpatients with nonpsychotic major depression who had not experienced remission with citalopram alone. In both papers, the primary outcome measure was remission with a score of <7 on the Hamilton Rating Scale for Depression (HRSD-17), while secondary outcome measurement of remission and response was done using the Quick Inventory of Depressive Symptomatology (QIDS-SR-16). Patients in this study were given the option to 1) augment their therapy by adding other agents or 2) switch to another therapy.

Study Rundown: This paper demonstrates that in patients with refractory depression despite vigorous SSRI treatment, augmenting therapy by adding buproprion or buspirone to existing SSRI therapy can help achieve remission in approximately 30% of patients. While there were no significant differences between the buproprion and buspirone groups in terms of remission rates, patients in the buproprion group were adherent to treatment for significantly longer periods of time, and experienced higher reductions in QIDS-SR-16 scores.

Click to read study in NEJM

RELATED REPORTS

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

Calorie restriction and low-fat diets may reduce depression in individuals with higher cardiometabolic risk

Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes

In-Depth [randomized, controlled trial]: The use of medications to augment SSRI therapy is common practice in the treatment of depression, though no previous randomized controlled trials had explored this issue. A total of 565 patients were recruited and randomized to either receive 1) sustained-release buproprion or 2) buspirone, in addition to citalopram, an SSRI.

There were no significant differences in remission rates between the two groups based on HSRD-17 scores (29.7% for buproprion group, 30.1% for buspirone group). Similarly, remission and response rates based on QIDS-SR-16 scores were not significantly different between the two groups. Patients in the buproprion group were adherent to treatment for significantly longer than those in the buspirone group (10.2 weeks vs. 9.2 weeks, P=0.01). Moreover, patients in the buproprion group experienced significantly higher reductions in QIDS-SR-16 scores at the end of the study when compared to the buspirone group.

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: depressionserotoninSSRIStart Dstartd
Previous Post

Untreated breast milk linked to CMV transmission

Next Post

Aggressive blood pressure control may be beneficial for intracerebral hemorrhage [INTERACT2]

RelatedReports

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

June 20, 2025
Vegetarian diet may lower incidence of colorectal cancer
Psychiatry

Calorie restriction and low-fat diets may reduce depression in individuals with higher cardiometabolic risk

May 20, 2025
Poor olfaction linked to increased mortality in older adults
Endocrinology

Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes

February 24, 2025
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Chronic Disease

Interruptive clinical decision supports may be more sensitive for suicide screening

January 8, 2025
Next Post
Aggressive blood pressure control may be beneficial for intracerebral hemorrhage [INTERACT2]

Aggressive blood pressure control may be beneficial for intracerebral hemorrhage [INTERACT2]

In-flight medical emergencies: syncope, respiratory, and gastrointestinal most common

In-flight medical emergencies: syncope, respiratory, and gastrointestinal most common

Antidepressant may reduce mental stress-induced myocardial ischemia (REMIT Trial)

Common painkillers increase risk of heart problems and death: meta-analysis

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.